FindTrial
Sign In

Treatment Program for Anemia in AIDS Patients

Treatment Program for Anemia in AIDS Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00002022
Enrollment
Unknown
Registered
2001-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cytopenias, HIV Infections

Keywords

Recombinant Proteins, Drugs, Investigational, Erythropoietin, Acquired Immunodeficiency Syndrome, Anemia, Zidovudine

Brief summary

The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.

Interventions

DRUGEpoetin alfa

Sponsors

R W Johnson Pharmaceutical Research Institute
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Exclusion criteria

Co-existing Condition: Patients with the following are excluded: * Life expectancy \< 3 months. * = or \< grade 4 performance score. * AIDS-related dementia. * Uncontrolled hypertension. * Acute symptomatic opportunistic infection or other AIDS-defining illness. Patients with the following are excluded: * Life expectancy \< 3 months. * = or \< grade 4 performance score. * AIDS-related dementia. * Uncontrolled hypertension. * Acute symptomatic opportunistic infection or other AIDS-defining illness. Patients must have: * A clinical diagnosis of AIDS. * Hematocrit \< 30 percent. * Endogenous serum erythropoietin level = or \< 500 U/ml. * A life expectancy = or \> 3 months. * \> Grade 4 performance score.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026